X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with Orchid Chemicals - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs ORCHID PHARMA LTD - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA ORCHID PHARMA LTD ABBOTT INDIA/
ORCHID PHARMA LTD
 
P/E (TTM) x 41.6 -0.7 - View Chart
P/BV x 10.4 0.5 2,119.4% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 ABBOTT INDIA   ORCHID PHARMA LTD
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-16
ORCHID PHARMA LTD
Sep-13
ABBOTT INDIA/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs6,015194 3,100.5%   
Low Rs3,70735 10,591.4%   
Sales per share (Unadj.) Rs1,236.9276.5 447.4%  
Earnings per share (Unadj.) Rs122.2-79.2 -154.2%  
Cash flow per share (Unadj.) Rs129.0-43.5 -296.8%  
Dividends per share (Unadj.) Rs35.000-  
Dividend yield (eoy) %0.70-  
Book value per share (Unadj.) Rs521.253.9 966.4%  
Shares outstanding (eoy) m21.2570.45 30.2%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.90.4 948.9%   
Avg P/E ratio x39.8-1.4 -2,752.3%  
P/CF ratio (eoy) x37.7-2.6 -1,430.3%  
Price / Book Value ratio x9.32.1 439.3%  
Dividend payout %28.60-   
Avg Mkt Cap Rs m103,2968,067 1,280.6%   
No. of employees `0003.02.8 105.6%   
Total wages/salary Rs m3,3702,527 133.4%   
Avg. sales/employee Rs Th8,891.86,956.1 127.8%   
Avg. wages/employee Rs Th1,140.0902.5 126.3%   
Avg. net profit/employee Rs Th878.3-1,993.0 -44.1%   
INCOME DATA
Net Sales Rs m26,28419,477 134.9%  
Other income Rs m504407 123.9%   
Total revenues Rs m26,78919,884 134.7%   
Gross profit Rs m3,6651,103 332.4%  
Depreciation Rs m1442,519 5.7%   
Interest Rs m85,227 0.2%   
Profit before tax Rs m4,017-6,236 -64.4%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0511 0.0%   
Tax Rs m1,421-125 -1,135.0%   
Profit after tax Rs m2,596-5,580 -46.5%  
Gross profit margin %13.95.7 246.3%  
Effective tax rate %35.42.0 1,761.9%   
Net profit margin %9.9-28.7 -34.5%  
BALANCE SHEET DATA
Current assets Rs m14,44611,014 131.2%   
Current liabilities Rs m4,72532,060 14.7%   
Net working cap to sales %37.0-108.1 -34.2%  
Current ratio x3.10.3 890.0%  
Inventory Days Days5195 54.2%  
Debtors Days Days2034 58.3%  
Net fixed assets Rs m1,11329,440 3.8%   
Share capital Rs m213705 30.2%   
"Free" reserves Rs m10,8082,043 529.1%   
Net worth Rs m11,0763,800 291.5%   
Long term debt Rs m09,018 0.0%   
Total assets Rs m16,24146,510 34.9%  
Interest coverage x497.0-0.2 -257,333.7%   
Debt to equity ratio x02.4 0.0%  
Sales to assets ratio x1.60.4 386.5%   
Return on assets %16.0-0.8 -2,109.9%  
Return on equity %23.4-146.9 -16.0%  
Return on capital %36.3-3.7 -973.1%  
Exports to sales %0.637.9 1.6%   
Imports to sales %12.622.6 55.9%   
Exports (fob) Rs m1627,378 2.2%   
Imports (cif) Rs m3,3224,406 75.4%   
Fx inflow Rs m2687,513 3.6%   
Fx outflow Rs m3,9275,649 69.5%   
Net fx Rs m-3,6591,865 -196.3%   
CASH FLOW
From Operations Rs m2,5141,682 149.5%  
From Investments Rs m-800-9,860 8.1%  
From Financial Activity Rs m-8036,644 -12.1%  
Net Cashflow Rs m912-1,535 -59.4%  

Share Holding

Indian Promoters % 0.0 32.3 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 4.6 171.7%  
FIIs % 0.1 3.3 3.0%  
ADR/GDR % 0.0 4.6 -  
Free float % 17.1 55.3 30.9%  
Shareholders   18,270 84,811 21.5%  
Pledged promoter(s) holding % 0.0 54.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  FULFORD INDIA  ALEMBIC PHARMA  ELDER PHARMA  

Compare ABBOTT INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day in Red; Realty Stocks Top Losers(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day on a dull note.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Jan 16, 2018 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA - PLETHICO PHARMA COMPARISON

COMPARE ABBOTT INDIA WITH

MARKET STATS